Synonym
Wofapyrin; Reopin G; Rheopyrine;
IUPAC/Chemical Name
A name could not be generated for this structure.
InChi Key
WEEYYYSUUWVFOJ-UHFFFAOYSA-M
InChi Code
InChI=1S/C19H20N2O2.C13H17N3O.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11;/h4-13,22H,2-3,14H2,1H3;5-9H,1-4H3;/q;;+1/p-1
SMILES Code
CCCCC1=C(N(c2ccccc2)N(c3ccccc3)C1=O)[O-].CN(C4=C(N(N(c5ccccc5)C4=O)C)C)C.[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
561.66
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: SEIDEL K. [Wofapyrin and butalidon in the treatment of rheumatic diseases]. Dtsch Gesundheitsw. 1955 May 26;10(21):741-4. German. PubMed PMID: 13241088.
2: BAYER F, WUST G. [Antipyretic and antiphlogistic effects of irgapyrine (wofapyrin) in pulmonary tuberculosis]. Munch Med Wochenschr. 1956 Dec 14;98(50):1724-6. German. PubMed PMID: 13387617.
3: FLORIAN J. [Stomach & intestinal hemorrhage after wofapyrin therapy]. Dtsch Gesundheitsw. 1957 Oct 31;12(44):1362-4. German. PubMed PMID: 13500902.
4: WOLFRAM G. [Toxicodermia after wofapyrin]. Dtsch Gesundheitsw. 1960 Apr 7;15:722-9. German. PubMed PMID: 13845735.
5: STEIMER R. [Use of wofapyrin in otorhinolaryngological diseases]. Dtsch Gesundheitsw. 1956 Jan 12;11(2):70-1. German. PubMed PMID: 13305266.
6: DUSEBERG G. [Wofapyrin in the treatment of adnexa uteri]. Z Arztl Fortbild (Jena). 1955 Feb 15;49(4):132. German. PubMed PMID: 14374715.
7: BAYER F, WUST G. [Treatment of influenza with irgapyrin (wofapyrin)]. Arztl Wochensch. 1956 Dec 14;11(50):1119-20. German. PubMed PMID: 13394484.
8: KAISER W, MORGENSTERN A. [Dangers and side-effects of management with injections of irgapyrin (wofapyrin). 3. Etiology of the irgapyrin (wofapyrin) edema]. Z Gesamte Inn Med. 1956 Oct 1;11(19):899-902. German. PubMed PMID: 13401897.
9: Schwarz F, Thiele R. [On the effect of the aminopyrine-phenylbutazone combination (wofapyrin) on Ranvier's nodes of nerves in cold-blooded animals]. Acta Biol Med Ger. 1966;17(1):87-95. German. PubMed PMID: 5982734.
10: HOLLMANN W, FENGLER A. [Treatment of the inflammation of the lungs with special reference to pyramidon and irgapyrin or wofapyrin]. Z Gesamte Inn Med. 1956 Apr 15;11(8):350-5. German. PubMed PMID: 13353285.
11: MORGENSTERN A, KAISER W, PFENNIGSDORF G. [Experimental animal studies on the etiology of edema propensity in wofapyrin treatment]. Z Gesamte Inn Med. 1956 May 1;11(9):427-8. German. PubMed PMID: 13353302.
12: KLINSER F. [Contribution to the prophylaxis of mastitis by irgapyrin]. Munch Med Wochenschr. 1960 May 13;102:1025-7. German. PubMed PMID: 14409923.
13: Sioshansi S, Ehdaivand S, Cramer C, Lomme MM, Price LL, Wazer DE. Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy. Cancer. 2012 Aug 15;118(16):3893-8. doi: 10.1002/cncr.27376. Epub 2012 Jan 3. PubMed PMID: 22864932.
14: LEUXNER E, PULVER R. [Administration of irgapyrin in pregnancy and puerperium]. Munch Med Wochenschr. 1956 Jan 20;98(3):84-6. German. PubMed PMID: 13288560.
15: Ivlev AS, Polunina TE. [Drug-induced lesion of the liver]. Voen Med Zh. 1987 Jun;(6):60-1. Russian. PubMed PMID: 3660719.
16: BERTHOUD E. [The effect of irgapyrin on renal functions]. Helv Med Acta. 1952 Oct;19(4-5):428-33. Undetermined Language. PubMed PMID: 13021794.
17: HOHFELD HH. [Liver damage caused by irgapyrin & butazolidin therapy]. Medizinische. 1958 Feb 15;2(7):281-2. German. PubMed PMID: 13516265.
18: GUTTMANN C. [Modern drugs which proved to be useful: irgapyrin, thomapyrin, merfen]. Zahnarztl Rundsch. 1955 Mar 5;64(5):115-6. German. PubMed PMID: 14374620.
19: Hernández C, Aragonés N, Estanyol N, Bartra J, Castillo I, Villalonga A. [Two cases of anaphylactic shock after metamizol given during postoperative recovery]. Rev Esp Anestesiol Reanim. 2004 Mar;51(3):168-9. Spanish. PubMed PMID: 15200191.
20: KOWALEWSKI S, ROTTHAUWE HW, HAUKE H. [3 CASES OF POISONING IN CHILDHOOD WITH IRGAPYRIN, BUTAZOLIDIN AND TOMANOL]. Ann Paediatr. 1964;202:43-57. German. PubMed PMID: 14112916.
